If your employer or health plan offers Omada, Virta or Vida, you may already have access to GLP-1 support that costs you nothing. Most people never check, and these programmes are structurally different from anything you can buy directly.
Why this is the first thing to check
Almost every provider on this site sells you something. Employer and health-plan programmes do not: they are bought by your employer, insurer or benefits platform on behalf of a population, and the member typically pays nothing. If you are eligible and do not know it, you are paying for something you could already have.
They are also aiming at a different target. Telehealth competes on the price of the molecule. These programmes compete on outcomes over years, because that is what their buyers measure them on, which pushes them toward the things medication alone does not do: protein intake, resistance training, behaviour change, and what happens when you stop.
The three major programmes compared
| Programme | Core approach | What is distinctive |
|---|---|---|
| Omada Health | GLP-1 companion support, with prescribing as a separate track | Muscle preservation and post-medication maintenance, with published discontinuation data |
| Virta Health | Nutrition-first therapy, with or without medication | Peer-reviewed research on deprescribing, and an explicit off-ramp |
| Vida Health | Full virtual clinic with integrated prescribing | Registered dietitians and mental health support inside the care team |
All three are sold to employers, health plans and benefits platforms rather than to individuals. Availability depends entirely on what your sponsor purchased.
Omada: the muscle problem
Omada's materials cite research suggesting muscle loss accounts for 25 to 39 percent of total weight lost during the first three to six months of GLP-1 treatment. Its programme is built around countering that with protein guidance, resistance training from a physical activity specialist, and behavioural support.
Its most interesting published claim concerns what happens after. Omada reports that 63 percent of members maintained or continued losing weight one year after stopping medication, with an average weight change of 0.8 percent. That is a company analysis rather than an independent trial, but it addresses the question most people on a GLP-1 eventually face.
Virta: the off-ramp
Virta comes at it from the opposite direction. Its argument to employers is that GLP-1 costs are rising two to four times for the drug class alone and that 68 percent of GLP-1 spend is wasted without provider and lifestyle support. It offers nutrition therapy as an alternative to medication, a companion to it, or a deliberate off-ramp from it.
It backs the off-ramp with peer-reviewed work: a propensity score matched cohort study published in Diabetes Ther in 2024 reporting that patient weight did not significantly increase at 6 or 12 months after GLP-1 deprescription. Virta also publishes long-run figures of 12 percent weight loss at one year, 11 percent at two years and 9 percent at three and a half.
A structural point worth understanding
Virta puts 100 percent of first-year employer fees at risk against a 0 percent GLP-1 trend guarantee. It states explicitly that these guarantees are based on programme design and do not influence provider clinical decision-making. That is the right disclosure to make, and it is worth knowing the incentive exists so you can ask your clinician directly if deprescribing is raised with you.
Vida: the full care team
Vida Health is the closest of the three to a conventional clinic. It provides physicians and advanced practitioners, registered dietitians, behaviour change coaches and mental health support, and incorporates GLP-1 medication where clinically appropriate as one part of a plan rather than as the product.
Its stated position is that medication alone is not enough to improve long-term health. Every care plan is paired with nutrition counselling, self-directed cognitive behavioural therapy and ongoing monitoring. Registered dietitian access in particular addresses the protein problem more directly than generic coaching.
How to find out whether you have access
- Check your benefits portal for weight management, metabolic health or chronic condition programmes
- Search your employer's benefits guide for Omada, Virta, Vida, Noom or Teladoc by name
- Ask HR or your benefits administrator directly, since these are often under-communicated
- Check your health plan's member portal separately, as insurers buy these independently of employers
- Each programme runs its own eligibility checker, which is the fastest way to confirm
- If you have a spouse or partner with coverage, check theirs too, as family eligibility is common
What these programmes will not do
They will not get you medication your plan does not cover. Omada and Vida operate inside the pharmacy benefit, so if your formulary excludes GLP-1s for weight loss, the programme does not change that. It gives you support around the problem, not a way round it.
They also offer no compounded fallback. If your coverage is declined and you cannot afford brand-name self-pay pricing, you would be looking at the routes covered in our retail pharmacy comparison or the compounded telehealth market instead.
How they compare with what you can buy
On cost
No contest where you are eligible. A programme costing you nothing beats a $99 to $225 monthly telehealth subscription, and medication runs through your pharmacy benefit rather than a cash price.
On medication access
Telehealth wins if your plan will not cover GLP-1s. Compounded programmes have no formulary to satisfy, which is precisely why the market exists.
On clinical depth
Employer programmes win comfortably. A dietitian, a physical activity specialist and mental health support is not something a $99 compounded subscription provides.
On speed
Telehealth wins. A two-minute assessment and medication in four days is faster than enrolling in a benefits programme and working through prior authorisation.
The honest summary
Check your benefits before you pay anyone. If you have access to one of these programmes, use it, and if your plan also covers the medication then you are in the best position available. If you are eligible for the programme but not the medication, the programme is still worth having alongside a self-pay route, because the behavioural side is the part that determines whether the result lasts.
And if you have no employer coverage at all, the closest equivalents you can approach directly are knownwell, which bills insurance for visits, and Calibrate, which works through insurance for medication coverage.
Frequently Asked Questions
How do I know if my employer offers a GLP-1 programme?
Check your benefits portal for weight management or metabolic health programmes, search your benefits guide for Omada, Virta, Vida, Noom or Teladoc by name, and ask HR directly. Each programme also runs its own eligibility checker, which is the fastest way to confirm.
Do employer GLP-1 programmes cost anything?
Typically nothing to the member, because the employer, health plan or benefits platform pays. Medication costs still run through your pharmacy benefit at your plan's copay.
What is the difference between Omada, Virta and Vida?
Omada focuses on GLP-1 companion support, muscle preservation and maintaining weight after stopping. Virta is nutrition-first and offers medication, a drug-free alternative or a deliberate off-ramp. Vida is a full virtual clinic with physicians, dietitians and mental health support alongside prescribing.
Can these programmes get me medication my plan will not cover?
No. They operate inside the pharmacy benefit, so a formulary exclusion still applies. They provide support around the problem rather than a route around it.
Is deprescribing being pushed for cost reasons?
It is a fair question to ask. Virta puts employer fees at risk against a GLP-1 trend guarantee and states explicitly that this does not influence provider clinical decision-making, with all medication decisions made by providers using independent judgment. Knowing the incentive exists means you can raise it with your clinician directly.
Are these better than paying for telehealth?
On cost and clinical depth, comfortably, where you are eligible. On speed and on access when your plan excludes GLP-1s, telehealth still wins, which is why the compounded market exists.
What if I have no employer coverage?
knownwell bills insurance for visits and runs an advocacy team pursuing medication coverage, and Calibrate works through insurance for coverage. Retail pharmacy routes are also now competitive for self-pay patients.
Medical Disclaimer
This article is for general information only and is not medical advice, a diagnosis, or a treatment recommendation. GLP-1 medications are prescription drugs with real risks and contraindications. Only a licensed clinician who knows your history can decide whether any medication is appropriate for you. Pricing, programmes and policies described here reflect what providers published at the time of writing and change frequently; verify everything directly before enrolling. See our full medical disclaimer.